Amarin Corporation PLC Market Cap ($252.68 Million)
Market Cap & Net Worth: Amarin Corporation PLC (AMRN)
Amarin Corporation PLC market cap. Amarin Corporation PLC (NASDAQ:AMRN) has a market capitalization of $252.68 Million ($252.68 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15360 globally and #3657 in its home market, demonstrating a -0.33% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Amarin Corporation PLC's stock price $12.05 by its total outstanding shares 20969109 (20.97 Million). Also see Amarin Corporation PLC operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Amarin Corporation PLC Market Cap History (2015–2026)
Amarin Corporation PLC market cap history from 2015 to 2026. Data shows growth from $39.63 Million to $252.68 Million (17.76% CAGR). Check current stock price of Amarin Corporation PLC for real-time trading data and today's change.
Index Memberships
Amarin Corporation PLC is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.01% | #405 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1496 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.01% | #211 of 263 |
Weight: Amarin Corporation PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Amarin Corporation PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Amarin Corporation PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore AMRN net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.37x
Amarin Corporation PLC's market cap is 1.37 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $64.58 Million | $130.08 Million | -$86.35 Million | 0.50x | N/A |
| 2017 | $84.09 Million | $181.10 Million | -$67.86 Million | 0.46x | N/A |
| 2018 | $285.39 Million | $229.21 Million | -$116.44 Million | 1.25x | N/A |
| 2019 | $449.58 Million | $429.75 Million | -$22.64 Million | 1.05x | N/A |
| 2020 | $102.54 Million | $614.06 Million | -$18.00 Million | 0.17x | N/A |
| 2021 | $70.67 Million | $583.19 Million | $7.73 Million | 0.12x | 9.14x |
| 2022 | $25.37 Million | $369.19 Million | -$105.80 Million | 0.07x | N/A |
| 2023 | $18.24 Million | $306.91 Million | -$59.11 Million | 0.06x | N/A |
| 2024 | $10.17 Million | $228.61 Million | -$82.18 Million | 0.04x | N/A |
| 2025 | $292.62 Million | $213.65 Million | -$38.80 Million | 1.37x | N/A |
Competitor Companies of AMRN by Market Capitalization
Companies near Amarin Corporation PLC in the global market cap rankings as of November 4, 2026. Also see AMRN asset base for a full breakdown of the balance sheet.
Key companies related to Amarin Corporation PLC by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #14 globally with a market cap of $1.06 Trillion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #20 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #29 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #43 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #14 | Eli Lilly and Company | NYSE:LLY | $1.06 Trillion | $1409.38 |
| #20 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #29 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $266.17 |
| #43 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $286.00 |
Market Capitalization of Amarin Corporation PLC (2015–2026)
Market capitalization of Amarin Corporation PLC from 2015 to today. Between 2015 and today, Amarin Corporation PLC's market cap moved from $39.63 Million to $ 252.68 Million, with a yearly change of 17.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $252.68 Million | -13.65% |
| 2025 | $292.62 Million | +2777.32% |
| 2024 | $10.17 Million | -44.25% |
| 2023 | $18.24 Million | -28.10% |
| 2022 | $25.37 Million | -64.09% |
| 2021 | $70.67 Million | -31.08% |
| 2020 | $102.54 Million | -77.19% |
| 2019 | $449.58 Million | +57.53% |
| 2018 | $285.39 Million | +239.40% |
| 2017 | $84.09 Million | +30.19% |
| 2016 | $64.58 Million | +62.96% |
| 2015 | $39.63 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Amarin Corporation PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $252.68 Million USD |
| MoneyControl | $252.68 Million USD |
| MarketWatch | $252.68 Million USD |
| marketcap.company | $252.68 Million USD |
| Reuters | $252.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Amarin Corporation PLC
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The compa… Read more